GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oncodesign Precision Medicine SA (XPAR:ALOPM) » Definitions » 3-Year ROIIC %

Oncodesign Precision Medicine (XPAR:ALOPM) 3-Year ROIIC % : -873.59% (As of Dec. 2023)


View and export this data going back to 2022. Start your Free Trial

What is Oncodesign Precision Medicine 3-Year ROIIC %?

3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year. Oncodesign Precision Medicine's 3-Year ROIIC % for the quarter that ended in Dec. 2023 was -873.59%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

The industry rank for Oncodesign Precision Medicine's 3-Year ROIIC % or its related term are showing as below:

XPAR:ALOPM's 3-Year ROIIC % is ranked worse than
92.27% of 1358 companies
in the Biotechnology industry
Industry Median: -13.43 vs XPAR:ALOPM: -873.59

Oncodesign Precision Medicine 3-Year ROIIC % Historical Data

The historical data trend for Oncodesign Precision Medicine's 3-Year ROIIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oncodesign Precision Medicine 3-Year ROIIC % Chart

Oncodesign Precision Medicine Annual Data
Trend Dec20 Dec21 Dec22 Dec23
3-Year ROIIC %
- - - -873.59

Oncodesign Precision Medicine Semi-Annual Data
Dec20 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
3-Year ROIIC % Get a 7-Day Free Trial - - - -873.59 -

Competitive Comparison of Oncodesign Precision Medicine's 3-Year ROIIC %

For the Biotechnology subindustry, Oncodesign Precision Medicine's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Oncodesign Precision Medicine's 3-Year ROIIC % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oncodesign Precision Medicine's 3-Year ROIIC % distribution charts can be found below:

* The bar in red indicates where Oncodesign Precision Medicine's 3-Year ROIIC % falls into.



Oncodesign Precision Medicine 3-Year ROIIC % Calculation

Oncodesign Precision Medicine's 3-Year ROIIC % for the quarter that ended in Dec. 2023 is calculated as:

3-Year ROIIC %=3-Year Incremental Net Operating Profit After Taxes (NOPAT)**/3-Year Incremental Invested Capital**
=( -8.1660128 (Dec. 2023) - -4.6454644 (Dec. 2020) )/( 2.264 (Dec. 2023) - 1.861 (Dec. 2020) )
=-3.5205484/0.403
=-873.59%***

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.


Oncodesign Precision Medicine  (XPAR:ALOPM) 3-Year ROIIC % Explanation

Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.

High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

Be Aware

It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.


Oncodesign Precision Medicine 3-Year ROIIC % Related Terms

Thank you for viewing the detailed overview of Oncodesign Precision Medicine's 3-Year ROIIC % provided by GuruFocus.com. Please click on the following links to see related term pages.


Oncodesign Precision Medicine Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
18 rue Jean Mazen, Dijon, FRA, 21000
Oncodesign Precision Medicine SA is a biopharmaceutical company specialised in precision medicine. Its mission is to provide patients with effective diagnostic and therapeutic solutions for resistant and metastatic cancers.

Oncodesign Precision Medicine Headlines

No Headlines